There are 2 articles on this stock available only to PRO subscribers.
Fri, Aug. 29, 11:07 AM
- Shares of thinly-traded nano cap Trovagene (TROV +11.5%) are up again today. Prices peaked at $7.09 this morning representing almost a 140% gain from the August 1 low of $2.97.
- Earlier in the week, the company reported results from two HPV studies that demonstrated encouraging results from its urine-based DNA test compared to commercially available products.
Thu, Aug. 28, 12:46 PM
Mon, Aug. 25, 12:30 PM
- Nano cap Trovagene (TROV +8.7%) presented results from two studies at the International Papillomavirus Conference in Seattle.
- The first oral presentation entitled, "Evaluation of Two Urine-Based HPV Assays in Comparison to Cervical HPV Detection and High-Grade CIN Among Women Attending a Colposcopy Clinic," detailed the results from the company's HR-HPV urine-based cell-free DNA assay from 72 women with abnormal Pap smears. Trovagene says its test was superior to a commercially available HPV screening test and comparable to Pap smears although no specific numbers were disclosed.
- The second presentation entitled, "A Comparison of Urine Collection Times for the Detection of High-Risk HPV Infection in Women," found that the detection rate of high risk HPV in the 37-woman test group was unaffected by the time of day the urine sample was collected or whether initial or mid-stream urine was used for testing. The detection rate for its HR-HPV assay was comparable to a commercially available kit for identifying high risk HPV+ women with CIN 2/3. Again, no specific numerical results were disclosed.
- CSO Mark Erlander says that the results from a larger blinded study comparing the sensitivity of urine versus cervical samples in detecting high-risk HPV patients with CIN 2/3 will be reported in Q1 2015.
Mon, Aug. 18, 12:46 PM
Mon, Aug. 18, 12:08 PM
- Shares of thinly-traded nano cap Trovagene (TROV +23.1%) jump on a 6x surge in volume albeit on turnover of only ~450K. Prices have rebounded ~50% from the August 1, 2014 low of $2.97. Shares peaked at $10.27 about a year ago (August 5, 2013).
- The firm is developing tests to detect cell-free DNA in urine samples.
- The company offers testing services via its in-house laboratory. It launched an LDT for the KRAS oncogene in March 2014, BRAF V600E in October 2013 and HPV in March 2013. It has yet to generate revenue from any of them, however. Its Q2 revenue of ~$56K consisted of royalties (NPM1) and a license fee ($10K).
Fri, Aug. 8, 8:01 AM
Tue, Jul. 1, 12:09 PM| Comment!
Tue, May. 20, 11:55 AM
- In what appears to be a hand-picked six-patient subset of a study of the prevalence of the BRAF V600E mutation in Erdheim-Chester disease, MD Anderson Cancer Center's Filip Janku finds that Trovagene's (TROV -2.4%) urine-based cell-free nucleic test for the mutation agrees with the six biopsy results. The theory is that the non-invasive diagnostic might be clinically useful considering that 60% of biopsies fail to provide enough tissue for testing.
- The fact that the company has yet generate any revenue from the BRAF testing service it launched six months ago reinforces the embryonic nature of urine-based oncogene testing. There is much work to be done to validate its clinical usefulness.
Fri, May. 16, 4:03 PM
- Shares of thinly traded nano cap Trovagene (TROV -8.8%) continue their slide today on 4x higher volume. Prices have now cratered 66% from the $10.27 August 5 high.
- The company reported Q1 results earlier in the week. Notable by their absence are any revenues from its much-ballyhooed transrenal nucleic acid tests. It launched a BRAF test in its CLIA lab in October of last year and a KRAS test in March, but no revenues have been generated yet. Per its 10-Q, all of its $111K in revenues come from NPM1 royalties.
Mon, May. 12, 6:06 PM
Mon, Mar. 17, 4:17 PM
Mon, Mar. 17, 8:27 AM
- Nano cap biotech Trovagene (TROV) debuts a KRAS genetic test that utilizes a urine sample instead of blood or tissue. The company offers the test as a service (laboratory-developed test). It detects the seven most common mutations in the KRAS oncogene.
- Consensus revenue estimates for 2013 and 2014 are $360K and $4.2M, respectively.
- 24 mutual funds have positions, up from 11 a year ago.
Nov. 15, 2013, 3:09 PM
- Trovagene (TROV +13.1%) is up double-digits after briefly trading in negative territory to start the day.
- The company reported a Q3 loss that was wider-than-expected Thursday evening, but that's not enough to make Aegis lose faith.
- "Although the firm's revenues were in-line with our modest estimates, the [wider] loss per share ... was driven primarily by higher-than-projected G&A spending [and the] negative impact of $1.3M from the change in fair value of warrants," analyst Raghuram Selvaraju says, before reiterating "revenue projections of $500K in 2013 and $4.6M in 2014."
- Buy rating maintained.
- Price target is $10.
Nov. 14, 2013, 4:15 PM
Oct. 1, 2013, 12:56 PM
- Shares of Trovagene (TROV +16.6%) soar as the company announces the availability of the first urine test for cancer mutation monitoring.
- The cell-free BRAF test detects and monitors V600E BRAF mutation, replacing tissue sample-based monitoring which "has limited practicality for patient monitoring due to costs, tumor heterogeneity and potential complications from the biopsy process." (PR)
- Aegis' Raghuram Selvaraju says the news marks "a significant milestone for the company and [is] a core component of the firm's strategy aimed at attaining profitability near-term."
Oct. 1, 2013, 12:47 PM
TROV vs. ETF Alternatives
Other News & PR